Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

The user experienced improved libido and erections after reducing DHT levels with 0.5mg of dutasteride once a week, despite previous side effects from finasteride. They are also on testosterone replacement therapy and have not noticed major personality changes.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

Dutasteride and finasteride have similar risk profiles despite Dutasteride blocking more types of 5AR in the brain. Some users report no mood issues with either drug, and it is suggested that Dutasteride's larger molecular size may limit its ability to cross the blood-brain barrier.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

Finasteride and dutasteride are still available in the EU, with a warning about potential suicidal thoughts. The benefits of these treatments are deemed greater than the risks.

The user has been taking 0.5 mg of finasteride daily for two months and is experiencing testicular ache, which they believe might be related to the medication. They plan to continue the treatment for a few more months despite the discomfort, hoping the side effects will subside.

The user stopped taking finasteride due to erectile dysfunction and was prescribed dutasteride by a dermatologist. Some users shared experiences of having fewer side effects with dutasteride, while others warned it might cause similar or worse side effects.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

Dutasteride improved hair density and thickness in men who didn't respond to finasteride, with some experiencing transient sexual dysfunction. Users discussed switching from finasteride to dutasteride, noting initial shedding but eventual hair improvement.

Finasteride is effective for treating male pattern baldness (MPB) with minimal side effects, and topical finasteride is similarly effective. Dutasteride is also effective but less understood, and Minoxidil is less effective than Finasteride.

Significant hair improvement was achieved using 1.25mg finasteride and 5mg oral minoxidil daily, with no side effects. The user increased the minoxidil dosage to 7.5mg after noticing minor thinning and plans to continue the routine.

PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.

The conversation is about hair loss treatments, specifically setipiprant, which the user is considering after experiencing side effects from finasteride and dutasteride. Another user mentions that setipiprant was ineffective in clinical trials.

Dutasteride is shown to be significantly more effective than finasteride for treating male androgenic alopecia. Users discuss the difficulty of obtaining dutasteride in some countries and share personal experiences with its effectiveness and side effects.

Minoxidil and finasteride are discussed for hair loss, with concerns about minoxidil's heart-related side effects. New treatments like PP405 are met with skepticism, often humorously noted as always being "five years away."

A 25-year-old is using 1.25mg finasteride six times a week and 5% topical minoxidil daily for hair loss. They are experiencing reduced libido and erectile issues, possibly due to stress, and are questioning if the finasteride dosage is affecting DHT suppression.

The conversation humorously discusses the use of pp405 for hair loss, with mentions of finasteride and minoxidil. Users joke about unusual side effects like growing extra body parts.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

Alternating Dutasteride with pumpkin seed oil may protect the spleen from damage caused by Dutasteride. Pumpkin seed oil's antioxidants help counteract oxidative stress and immune suppression.

A 45-year-old male experienced significant hair regrowth using 0.5 mg dutasteride and 1.5 mg minoxidil after initially starting with finasteride. He reports no major side effects, except increased hair growth in unwanted areas, and attributes his success to being a good responder to the medication.

Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.

PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.

The user experienced significant hair regrowth using a combination of oral minoxidil (5mg) and dutasteride (0.5mg) along with monthly mesotherapy injections. Despite the progress, the user plans to proceed with a hair transplant to address a receding hairline that hasn't fully responded to the treatment.

Finasteride increased the user's estrogen levels by 51%, causing concerns about gynecomastia and sleep issues. Despite potential side effects, the user prefers continuing finasteride to prevent hair loss, considering it essential for self-esteem.

Finasteride may affect prostate sensation and size, with some users reporting easier urination. Concerns exist about prostate shrinkage even at lower doses.

Using DIM and Calcium D-Glucarate to reduce finasteride side effects. Discussion includes dosage, brand, and product effectiveness.